Allogeneic HCT vs Standard Consolidation Chemotherapy for Intermediate-Risk AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial
JAMA Oncol 2023 Feb 09;[EPub Ahead of Print], M Bornhäuser, C Schliemann, J Schetelig, C Röllig, M Kramer, B Glass, U Platzbecker, A Burchert, M Hänel, LP Müller, S Klein, G Bug, D Beelen, W Rösler, K Schäfer-Eckart, C Schmid, E Jost, G Lenz, J Tischer, K Spiekermann, M Pfirrmann, H Serve, F Stölzel, N Alakel, JM Middeke, C Thiede, G Ehninger, WE Berdel, M StelljesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.